Cargando…

THE NATURE OF AUSTRALIA ANTIGEN AND ITS RELATION TO ANTIGEN-ANTIBODY COMPLEX FORMATION

There is considerable data to support the hypothesis that Australia antigen is an infectious agent that causes hepatitis in man. (a) Association with acute viral hepatitis. (b) Association with chronic hepatitis. (c) Virus-like appearance under the electron microscope (200-A particles). (d) Transmis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blumberg, Baruch S., Millman, Irving, Sutnick, Alton I., London, W. Thomas
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 1971
Materias:	Rheumatoid Arthritis and Other Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2139062/ https://www.ncbi.nlm.nih.gov/pubmed/19867378

Ejemplares similares

THE LOCALIZATION OF AUSTRALIA ANTIGEN BY IMMUNOFLUORESCENCE
por: Coyne(Zavatone), Veronica E., et al.
Publicado: (1970)

VASCULITIS IN ASSOCIATION WITH AUSTRALIA ANTIGEN
por: Gocke, David J., et al.
Publicado: (1971)

AUSTRALIA ANTIGEN (A HEPATITIS-ASSOCIATED ANTIGEN) : PURIFICATION AND PHYSICAL PROPERTIES
por: Millman, Irving, et al.
Publicado: (1970)

Role of Anti–Carbamylated Protein Antibodies Compared to Anti–Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First‐Degree Relatives, and Healthy Controls
por: Koppejan, H., et al.
Publicado: (2016)

Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts
por: Sun, Meng, et al.
Publicado: (2019)

Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis
por: Catrina, Anca, et al.
Publicado: (2021)

Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome
por: Fragoulis, George E, et al.
Publicado: (2018)

OCCURRENCE OF γ-GLOBULIN COMPLEXES IN SERUM AND JOINT FLUID OF RHEUMATOID ARTHRITIS PATIENTS: USE OF MONOCLONAL RHEUMATOID FACTORS AS REAGENTS FOR THEIR DEMONSTRATION
por: Winchester, R. J., et al.
Publicado: (1971)

Grip strength reduction in clinically suspect arthralgia: natural trajectories and improvement after treatment
por: Krijbolder, Doortje I, et al.
Publicado: (2023)

Antibodies to Cartilage Oligomeric Matrix Protein Are Pathogenic in Mice and May Be Clinically Relevant in Rheumatoid Arthritis
por: Ge, Changrong, et al.
Publicado: (2022)

Complex role of oestrogens in the risk and severity of rheumatoid arthritis in menopause
por: Cutolo, Maurizio, et al.
Publicado: (2023)

Peptidylarginine Deiminase Autoimmunity and the Development of Anti–Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten–Carrier Model
por: Auger, Isabelle, et al.
Publicado: (2020)

Antibodies against citrullinated proteins of IgA isotype are associated with progression to rheumatoid arthritis in individuals at-risk
por: Sokolova, Maria V, et al.
Publicado: (2023)

Is Anti–Citrullinated Protein Antibody–Positive Rheumatoid Arthritis Still a More Severe Disease Than Anti–Citrullinated Protein Antibody–Negative Rheumatoid Arthritis? A Longitudinal Cohort Study in Rheumatoid Arthritis Patients Diagnosed From 2000 Onward
por: Boer, Aleid C., et al.
Publicado: (2018)

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results
por: Van Hoovels, Lieve, et al.
Publicado: (2022)

Symptom Complexes at the Earliest Phases of Rheumatoid Arthritis: A Synthesis of the Qualitative Literature
por: Stack, Rebecca J, et al.
Publicado: (2013)

Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial
por: Akdemir, G, et al.
Publicado: (2016)

N‐Linked Glycans in the Variable Domain of IgG Anti–Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis
por: Hafkenscheid, Lise, et al.
Publicado: (2019)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
por: Saleem, Benazir, et al.
Publicado: (2022)

Association of Sputum Neutrophil Extracellular Trap Subsets With IgA Anti–Citrullinated Protein Antibodies in Subjects at Risk for Rheumatoid Arthritis
por: Okamoto, Yuko, et al.
Publicado: (2021)

‘More than just chitchat’: a qualitative study concerning the need and potential format of a peer mentor programme for patients with early rheumatoid arthritis
por: Van der Elst, Kristien, et al.
Publicado: (2021)

Differences in the Spectrum of Anti–Citrullinated Protein Antibody Fine Specificities Between Malaysian and Swedish Patients With Rheumatoid Arthritis: Implications for Disease Pathogenesis
por: Too, Chun Lai, et al.
Publicado: (2016)

Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study
por: Boman, Antonia, et al.
Publicado: (2019)

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

Association of Distinct Fine Specificities of Anti−Citrullinated Peptide Antibodies With Elevated Immune Responses to Prevotella intermedia in a Subgroup of Patients With Rheumatoid Arthritis and Periodontitis
por: Schwenzer, Anja, et al.
Publicado: (2017)

Recognition of Amino Acid Motifs, Rather Than Specific Proteins, by Human Plasma Cell–Derived Monoclonal Antibodies to Posttranslationally Modified Proteins in Rheumatoid Arthritis
por: Steen, Johanna, et al.
Publicado: (2019)

Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2018)

Combination of Two Monoclonal Anti–Citrullinated Protein Antibodies Induced Tenosynovitis, Pain, and Bone Loss in Mice in a Peptidyl Arginine Deiminase‐4–Dependent Manner
por: Krishnamurthy, Akilan, et al.
Publicado: (2022)

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
por: Visvanathan, Sudha, et al.
Publicado: (2019)

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
por: Nasonov, Evgeniy, et al.
Publicado: (2022)

IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 Samples
por: Kissel, Theresa, et al.
Publicado: (2022)

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
por: Wu, Chun, et al.
Publicado: (2022)

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
por: Schiff, Michael, et al.
Publicado: (2015)

Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association
por: van den Beukel, Michelle D, et al.
Publicado: (2023)

Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor
por: Ge, Changrong, et al.
Publicado: (2022)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022)

Complex Relationships of Smoking, HLA–DRB1 Genes, and Serologic Profiles in Patients With Early Rheumatoid Arthritis: Update From a Swedish Population‐Based Case–Control Study
por: Hedström, Anna Karin, et al.
Publicado: (2019)

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tba5g4np9lvpd19eoehtpteuf4